Also known as Macula Lutea Degeneration
Age-related macular degeneration (AMD) is a medical condition which usually affects older adults and results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. It occurs in "dry" and "wet" forms. It is a major cause of blindness and visual impairment in older adults (>50 years). Macular degeneration can make it difficult or impossible to read or recognize faces, although enough peripheral vision remains to allow other activities of daily life.Source: Wikipedia
Within all the people who go to their doctor with macular degeneration, 80% report having diminished vision, 45% report having spots or clouds in vision, and 25% report having symptoms of eye. The symptoms that are highly suggestive of macular degeneration are diminished vision, spots or clouds in vision, symptoms of eye, blindness, foreign body sensation in eye, double vision, eye burns or stings, and bleeding from eye, although you may still have macular degeneration without those symptoms.
Patients with macular degeneration often receive ophthalmic examination and evaluation, ophthalmologic and otologic diagnosis and treatment, other therapeutic procedures on eyelids; conjunctiva; cornea, other intraocular therapeutic procedures, other therapeutic procedures, diagnostic procedures on eye, lens and cataract procedures and other extraocular muscle and orbit therapeutic procedures .
|Ophthalmic examination and evaluation (Eye exam)|
|Ophthalmologic and otologic diagnosis and treatment||$64|
|Other therapeutic procedures on eyelids; conjunctiva; cornea||$962|
|Other intraocular therapeutic procedures||$705|
|Other therapeutic procedures||$17|
|Diagnostic procedures on eye||$114|
|Lens and cataract procedures||$1016|
|Other extraocular muscle and orbit therapeutic procedures||$671|
The most commonly prescribed drugs for patients with macular degeneration include bevacizumab (avastin), tropicamide ophthalmic, phenylephrine (duramax), prednisolone ophthalmic, latanoprost, ranibizumab ophthalmic, proparacaine ophthalmic, brimonidine ophthalmic, travoprost (travatan), gatifloxacin (zymar), nepafenac ophthalmic, bimatoprost ophthalmic and benoxinate-fluorescein ophthalmic .
Groups of people at highest risk for macular degeneration include age 75+ years age 60-74 years. On the other hand, age 5-14 years and age < 1 years almost never get macular degeneration.